Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

Manali Kamdar, MD, Bradley Augustson, MBBS FRACP FRCPA, Young Rok Do, PhDMD, James Edwards, Mark Hertzberg, MBBS PhDFRACP FRCPA, Amanda Johnston, FRACP,FRCPA,MBBS,BMBS,MD, Jin Seok Kim, MD PhD, Frank P. Kroschinsky, MDMBA, Sonali M. Smith, MD, Don A. Stevens, MD, Annabelle Monnet, Ye Zhao, Yann Nouet, PhD MSc, Viktoriya Marinova

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136221

Published: 2020

Journal Articles

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-135999

Published: 2020

Journal Articles

Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Xinhua Li, Cindy Lin, Jin Seok Kim, MD PhD, Hiroshi Handa, MD PhD, Brian G.M. Durie, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139019

Published: 2020

Journal Articles

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Ola Landgren, MD PhD, Katja Weisel, MD, Laura Rosinol Dachs, Philippe Moreau, MD, Mehmet Turgut, MD, Roman Hajek, MD PhD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Jin Seok Kim, MD PhD, Jianqi Zhang, Ning Go, PhD, Christopher L. Morris, PhDMD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-141291

Published: 2020

Journal Articles

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136150

Published: 2020

Journal Articles

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136265

Published: 2020

Journal Articles

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

Regis Peffault De Latour, MD PhD, Jeffrey Szer, MBBS, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Jin Seok Kim, MD PhD, Caroline I. Piatek, MD, Alexander D. Kulagin, MD PhD, Anita Hill, Jimmy Wang, Ji Yu, Masayo Ogawa, MD FAAP, Hubert Schrezenmeier, Jong Wook Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140777

Published: 2020

Journal Articles

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Regis Peffault De Latour, MD PhD, Simona Sica, MD PhD, Julia Ramos, MD, Jules Hernández-Sánchez, PhD, Jin Seok Kim, MD PhD, Anna Kiialainen, PhD, Sung-Soo Yoon, MD PhD, Sasha Sreckovic, MD, Antoine Soubret, PhD, Haruhiko Ninomiya, MD PhD, Alexandre Sostelly, PhD, Jens Panse, MD, Simon Buatois, PharmD, PhD, Hubert Schrezenmeier, Ido Paz-Priel, MD, Jun-ichi Nishimura, MD PhD, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-135841

Published: 2020

Journal Articles

YAP and TAZ in Fibroblastic Reticular Cells Support Hematopoiesis and Retention of Lymphocytes in Lymph Nodes

Hyunsoo Cho, MD PhD, Yu Ri Kim, MD, Jieun Jang, MD, Haerim Chung, MD, Soo-Jeong Kim, Sung Yong Choi, Bae Hosung, Ralf Adams, Burkhard Ludewig, PhD, Jin Seok Kim, MD PhD, June-Won Cheong, MD PhD, Yoo Hong Min, MD PhD, Gou Young Koh

Blood (2019) 134 (Supplement_1): 3595.

https://doi.org/10.1182/blood-2019-124625

Published: 2019

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Ho-Young Yhim, MD, Cheolwon Suh, Seok Jin Kim, MD PhD, Deok-Hwan Yang, MD PhD, Hyeon-Seok Eom, MD, Kyoung Ha Kim, MD PhD, Yong Park, Jin Seok Kim, MD PhD, Hyo Jung Kim, MD PhD, Dok Hyun Yoon, MD PhD, Won Seog Kim, MD PhD, Jae-Yong Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 4076.

https://doi.org/10.1182/blood-2019-122631

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

Peripheral Blood Absolute Lymphocyte Count at Diagnosis As a New Prognostic Factor in Acute Myeloid Leukemia with t(8;21) Patients

Jieun Jang, MD, Yu Ri Kim, MD, Hyunsoo Cho, MD PhD, Haerim Chung, MD, Soo-Jeong Kim, MD, Jin Seok Kim, MD PhD, June-Won Cheong, MD PhD, Yoo Hong Min, MD PhD

Blood (2019) 134 (Supplement_1): 5178.

https://doi.org/10.1182/blood-2019-128027

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Anita Hill, MD PhD, Caroline I. Piatek, Régis Peffault de Latour, MD PhD, Lily LL Wong, MD FRCPath, Richard A. Wells, MD DPhil, Robert A. Brodsky, MD, Jin Seok Kim, MD PhD, Junichi Nishimura, MD PhD, Philip Kuriakose, MD, Rodrigo Pavani, Peng Liu, Stephan Ortiz, RPh, PhD, Hubert Schrezenmeier, MD, Jong-Wook Lee, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 952.

https://doi.org/10.1182/blood-2019-128929

Published: 2019

Journal Articles

The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Blood (2018) 132 (Supplement 1): 535.

https://doi.org/10.1182/blood-2018-99-113274

Published: 2018

Journal Articles

Recovery of Specific Subsets of Natural Killer and T Cells Highly Associated with Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in Acute Leukemia

Jieun Jang, MD, Haerim Chung, MD, Yu Ri Kim, MD, Hoi-kyung Jeung, Ju-In Eom, So-Young Seol, Soo-Jeong Kim, MD, Jin Seok Kim, MD, PhD, June-Won Cheong, MD PhD, Yoo Hong Min, MD PhD

Blood (2018) 132 (Supplement 1): 4581.

https://doi.org/10.1182/blood-2018-99-115786

Published: 2018

Journal Articles

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Seok Jin Kim, MD PhD, Yong Park, MD, Yeung-Chul Mun, Jin Seok Kim, MD PhD, Kihyun Kim, MD PhD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2018-99-115447

Published: 2018

NARROW

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

YAP and TAZ in Fibroblastic Reticular Cells Support Hematopoiesis and Retention of Lymphocytes in Lymph Nodes

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Peripheral Blood Absolute Lymphocyte Count at Diagnosis As a New Prognostic Factor in Acute Myeloid Leukemia with t(8;21) Patients

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

The SMART Anti-hC5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recovery of Specific Subsets of Natural Killer and T Cells Highly Associated with Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in Acute Leukemia

The Assessment of Health-Related Quality of Life in Relapsed or Refractory Myeloma Patients Receiving Lenalidomide and Low Dose Dexamethasone: A Result of Hola Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only